Downloads: 1
| # | nci_id | nct_id | official_title | inclusion_indicaInclusionor | description | Text | Boolean |
|---|---|---|---|---|---|---|---|
| 1 | NCI-2009-00336 | NCT00392327 | Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients | nan | nan | nan | nan |
| 2 | NCI-2009-00470 | NCT00632853 | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide | nan | nan | nan | nan |
| 3 | NCI-2009-00595 | NCT00719303 | Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? | nan | nan | nan | nan |
| 4 | NCI-2009-00603 | NCT00492778 | A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus | nan | nan | nan | nan |
| 5 | NCI-2009-00817 | NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (Cd20+) in Adults and Children with Previously Untreated Aggressive Non-Hodgkin's Lymphoma | Inclusion | Human immunodeficiency virus (HIV) negative | HIV excluded OR HIV UNKNOWN | C15175 = NO OR C15175=C17998 |
| 6 | NCI-2009-01057 | NCT00576654 | A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors | nan | nan | nan | nan |
| 7 | NCI-2011-00312 | NCT01012817 | A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) after Prior Platinum Containing First-Line Chemotherapy | Exclusion | Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive | HIV negative included: Immunocompromised excluded (unless due to corticosteroid usage) | C14139 = NO OR (C14139=NO AND C211=YES) AND (C15175 = NO OR C15175=C17998) |
| 8 | NCI-2011-00878 | NCT00956007 | A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer | Exclusion | Severe, active co-morbidity, defined as follows: * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients | AIDS excluded; immunocompromised excluded | (C2851=NO) AND (C14139 = NO) |
| 9 | NCI-2011-01915 | NCT00887146 | N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma | Exclusion | Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study | HIV positive and receiving antiretroviral therapy excluded; HIV positive and no immunopromised eligible. | (C15175=NO) OR (C15175=C17998) OR (C15175 = YES AND C94631 = NO) OR (C15175 = YES AND C14139 = NO) |
| 10 | NCI-2011-01972 | NCT00983697 | A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients | nan | nan | nan | nan |
| 11 | NCI-2011-01973 | NCT00980954 | Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy | Inclusion | Patients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol) | HIV Negative or HIV positive and CD4>= 350 | (C15175 = NO) OR (C15175 = C17998) OR (C15175 = YES AND C103810 >= 350 {cells}/mm3) |
| 12 | NCI-2011-01974 | NCT00981656 | A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging | Exclusion | Severe, active co-morbidity, defined as follows: * Acquired immune deficiency syndrome (AIDS) based upon the current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients | AIDS excluded; immunocompromised excluded | (C2851 = NO) AND (C14139 = NO) |
| 13 | NCI-2011-01975 | NCT00980460 | Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment | nan | nan | nan | nan |
| 14 | NCI-2011-01987 | NCT01013649 | A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma | Inclusion | Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed | HIV negative or HIV eligible if CD4 > 499 cell/mm3 and viral load < 50 copies/ml and HAART yes or no. | (C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C103810 > 499 {cells}/mm3 AND C92544 < 50 {copies}/ml) |
| 15 | NCI-2011-01992 | NCT02085408 | Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) | Inclusion | *B21Patients with known human immunodeficiency virus (HIV) infection are excluded *No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies | HIV positive excluded | C15175 = NO OR C15175=C17998 |
| 16 | NCI-2011-02000 | NCT01042522 | A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary | nan | nan | nan | nan |
| 17 | NCI-2011-02029 | NCT01096368 | Phase III Randomized Trial of Post-radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years | nan | nan | nan | nan |
| 18 | NCI-2011-02034 | NCT01118026 | Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL) | Inclusion | Patients with known human immunodeficiency virus (HIV) must have a CD4 count > 350 and be on concurrent antiretrovirals; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk | HIV positive if CD4 > 350 and on retrovirals. | (C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C103810 > 350 {cells}/mm3) |
| 19 | NCI-2011-02037 | NCT01101451 | Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy | nan | nan | nan | nan |
| 20 | NCI-2011-02073 | NCT02589938 | A Phase III Prospective Randomized Trial of Acupuncture for Treatment_x000D_ of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer | nan | nan | nan | nan |
| 21 | NCI-2011-02500 | NCT01366144 | An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors | Exclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible | HIV positive and antiretrovirals excluded; HIV positive without AIDS defining diagnosis included | (C15175 = NO) OR (C15175=C17998) OR C15175 = YES AND C94631 = NO) OR (C15175 = YES AND C2851 =NO) |
| 22 | NCI-2011-02515 | NCT01051635 | A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas | Exclusion | Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to, active or uncontrolled infection, immune deficiencies, known human immunodeficiency virus (HIV) infection requiring antiretroviral therapy, | HIV positive with antiretroviral therapy excluded | (C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C94631 = NO) |
| 23 | NCI-2011-02539 | NCT01226940 | A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas | Exclusion | Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | HIV positive with antiretroviral therapy excluded | (C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C94631 = NO) |
| 24 | NCI-2011-02592 | NCT01386385 | A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) | Inclusion | Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study | HIV positive with antiretroviral therapy excluded | (C15175 = NO) OR (C15175=C17998) OR (C14139=C17998) OR (C15175 = YES AND C94631 = NO) |
| 25 | NCI-2011-02594 | NCT01381718 | A Phase II Placebo-Controlled Trial of Modafinil to Improve_x000D_ Neurocognitive Deficits in Children Treated for a Primary Brain Tumor | nan | nan | nan | nan |
| 26 | NCI-2011-02599 | NCT01190930 | Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) | nan | nan | nan | nan |
| 27 | NCI-2011-02611 | NCT01231906 | A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma | nan | nan | nan | nan |
| 28 | NCI-2011-02623 | NCT01272037 | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer | nan | nan | nan | nan |
| 29 | NCI-2011-02660 | NCT01275664 | Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First Line Post-Operative Intraperitoneal Chemotherapy | nan | nan | nan | nan |
| 30 | NCI-2011-02673 | NCT01359592 | A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) | Inclusion | Patients must not be known to be human immunodeficiency virus (HIV)-positive | nan | (C15175 = NO) OR (C15175=C17998) |
| 31 | NCI-2011-02674 | NCT01368588 | Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial | Exclusion | Severe, active co-morbidity, defined as follows: * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients | AIDS excluded; immunocompromised excluded | (C2851 = NO) OR (C15175=C17998) AND (C14139 = NO) |
| 32 | NCI-2011-03458 | NCT01434316 | Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors | nan | nan | nan | nan |
| 33 | NCI-2011-03797 | NCT02883049 | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | nan | nan | nan | nan |
| 34 | NCI-2012-00095 | NCT01497444 | Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC | nan | nan | nan | nan |
| 35 | NCI-2012-00105 | NCT01503632 | A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL | nan | nan | nan | nan |
| 36 | NCI-2012-00112 | NCT01503086 | Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study | nan | nan | nan | nan |
| 37 | NCI-2012-00234 | NCT01515787 | A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision | nan | nan | nan | nan |
| 38 | NCI-2012-00680 | NCT01333046 | Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma | Exclusion | PROCUREMENT: Patients with active human immunodeficiency virus (HIV) positive at time of procurement (can be pending at the time of blood draw) | HIV positive excluded | (C15175 = NO) OR (C15175=C17998) |
| 39 | NCI-2012-00707 | NCT01556243 | Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC) | nan | nan | nan | nan |
| 40 | NCI-2012-00719 | NCT01573442 | Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias | nan | nan | nan | nan |
| 41 | NCI-2012-00860 | NCT01587352 | A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma | Exclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the cluster of differentiation (CD)4 count is < 200 cells/mm^3 within one month of study enrollment | HIV positive on antiretrovirals included if CD4 >= 200 | (C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C103810 > 200 {cells}/mm3) |
| 42 | NCI-2012-00864 | NCT01585805 | A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II) | Exclusion | Patients with a known active infection, e.g., hepatitis B virus or hepatitis C virus; human immunodeficiency virus (HIV)-positive patients who are otherwise well and who do not have evidence of significant immune compromise are eligible | HIV positive and healthy and not immunocompromised included | (C15175 = NO) OR (C15175=C17998) OR (C15175 = YES AND C115935 = YES AND C14139 = NO) |
| 43 | NCI-2012-01040 | NCT01638533 | A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction | Inclusion | Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigator | HIV positive eligible if CD4 > 250 | (C15175 = NO) AND (C15175 = C17998) AND (C15175 = YES AND C103810 > 250 {cells}/mm3) |
| 44 | NCI-2012-01695 | NCT01775475 | Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa | Inclusion | All participants must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load > 400 copies/mL who have been on antiretroviral therapy for more than 4 months can be enrolled if an alternative antiretroviral therapy (ART) regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment history; patients are not allowed to receive zidovudine (azidothymidine [AZT]) as part of concurrent chemotherapy and ART regimen, since it is myelosuppressive; zidovudine may be discontinued and substituted as clinically indicated prior to or at the time of enrollment *HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV-1 antigen or plasma HIV-1 ribonucleic acid (RNA) viral load > 1,000 copies/mL * WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load | antiviral therapy = Y and virological suppression =Y and immunocompromised =NO and viarl load > 400 copies/ML and antiretroviral therapy > 4 months and zidovudivine = NO | HIV=YES AND C94631=YES AND C14139=NO AND C947=NO |
| 45 | NCI-2012-01712 | NCT01695941 | A Phase I Study of MLN8237 in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma | Exclusion/Inclusion | Exclusion: HIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligible Inclusion: Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ cluster of differentiation 4 (CD4)+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES and HAART=No) or (HIV=YES and HAART=YES AND Cytochrome P450 3A4 Inhibitor=NO AND CD4>= 300 {cells}/mm3 AND Viral Load=undetectable AND AIDS=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES and C94631=No) or (C15175 =YES and C94631=YES AND C111373=NO AND C103810>= 300 {cells}/mm3 AND C92544=C111568 AND C2851=NO) |
| 46 | NCI-2012-01964 | NCT01595061 | A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) | nan | nan | nan | nan |
| 47 | NCI-2012-01967 | NCT01602666 | Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) | nan | nan | nan | nan |
| 48 | NCI-2012-01977 | NCT01622868 | Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG | nan | nan | nan | nan |
| 49 | NCI-2012-01990 | NCT01649089 | Evaluation of Physical Function and Quality of Life (QOL) before and after Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer | nan | nan | nan | nan |
| 50 | NCI-2012-01995 | NCT01674140 | Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy. | Inclusion | Patients known to be human immunodeficiency virus (HIV) positive may be enrolled if baseline cluster of differentiation (CD)4 count is > 500 cells/mm^3 AND not taking anti-retroviral therapy; patients with known hepatitis are not eligible unless there is a known negative hepatitis panel; (exception: previous history of hepatitis A infection that is not currently active is allowed); patients must not have any known uncontrolled underlying pulmonary disease | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND CD4>500 {cells}/mm3 AND HAART=NO) OR (C3096=NO) OR (C3096=Y AND Viral Load=0 {copies}/mm3 OR (C141405=NO) OR (C129452C=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C103810>500 {cells}/mm3 AND C94631=NO) OR (C3096=NO) OR (C3096=Y AND C92544=C111568 {copies}/mm3 OR (C141405=NO) OR (C129452C=NO) |
| 51 | NCI-2012-01998 | NCT01668719 | A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM) | Inclusion | Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration: * Cluster of differentiation (CD)4 cells >= 500/mm^3 * Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART * No zidovudine or stavudine as part of cART * Patients who are HIV+ and do not meet all of these criteria are not eligible for this study | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND CD4>=500 {cells}/mm3) AND ((HIV=YES AND cART=YES AND Viral Load<50 {copies}/mm3) OR (HIV =YES AND cART=NO AND Viral Load<25000 {copies}/mm3)) AND (Zidovudine=NO) AND (Stavudine=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C103810>=500 {cells}/mm3) AND ((C15175 =YES AND C94631=YES AND C92544<50 {copies}/mm3) OR (C15175 =YES AND C94631=NO AND C92544<25000 {copies}/mm3)) AND (C947=NO) AND (C1428=NO) |
| 52 | NCI-2012-02009 | NCT01711541 | Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck | Inclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible | HIV = NO or HIV = Y and HAART = NO | (C15175 = NO) OR (C15175 =C17998) or (C15175 = YES and C94631 = NO) |
| 53 | NCI-2012-02011 | NCT01711554 | A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma | nan | nan | nan | nan |
| 54 | NCI-2012-02020 | NCT01781468 | A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to_x000D_ Reduce Cancer-Related Fatigue in Patients with High Grade Glioma | nan | nan | nan | nan |
| 55 | NCI-2012-02045 | NCT01805076 | Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer | nan | nan | nan | nan |
| 56 | NCI-2012-02057 | NCT01730937 | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | Exclusion | Use of combination anti-retroviral therapy for human immunodeficiency virus (HIV) | HIV = NO or HIV = Y and HAART = NO | (C15175 = NO) OR (C15175 =C17998) or (C15175 = YES and C94631 = NO) |
| 57 | NCI-2012-02067 | NCT01349881 | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | nan | nan | nan | nan |
| 58 | NCI-2012-02078 | NCT01789684 | A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics_x000D_ Services Among Breast Cancer Patients | nan | nan | nan | nan |
| 59 | NCI-2012-02608 | NCT01863550 | Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) | Inclusion | STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria: * Cluster of differentiation (CD)4 cell count >= 350/mm^3 * No history of acquired immune deficiency syndrome (AIDS)-related illness * Not currently prescribed zidovudine or stavudine | STEP I: HIV=NO OR HIV=UNKNOWN OR (HIV=YES AND CD4>=350{cells}/mm3 AND AIDS=NO AND Zidovudine=NO AND Stavudine=NO) | STEP I: C15175=NO OR C15175=C17998 OR (C15175=YES AND C103810>=350{cells}/mm3 AND C2851=NO AND C947=NO AND C1428=NO) |
| 60 | NCI-2012-02767 | NCT01749397 | A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers | Exclusion | Immunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count > 400 and do not require antiretroviral therapy | (Immunocompromised=NO) OR (HIV=NO) OR (HIV =UNKNOWN) OR (HIV =Y AND CD4>400 {cells}/mm3 AND HAART=NO) | (C14139=NO) OR (C15175=NO) OR (C15175 =C17998) OR (C15175 =Y AND C103810>400 {cells}/mm3 AND C94631=NO) |
| 61 | NCI-2012-02869 | NCT01806129 | EROS: Engendering Reproductive Health within Oncologic Survivorship | nan | nan | nan | nan |
| 62 | NCI-2012-02875 | NCT01586403 | Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study | Exclusion | Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) | HIV = NO or HIV = Y or HBV = Y or HCV =Y | C15175 = NO OR C15175 =C17998 |
| 63 | NCI-2012-03124 | NCT01755195 | A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma | Exclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO) |
| 64 | NCI-2012-03125 | NCT01767194 | A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma | nan | nan | nan | nan |
| 65 | NCI-2012-03173 | NCT01089101 | A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma | nan | nan | nan | nan |
| 66 | NCI-2012-03198 | NCT01872975 | A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy | nan | nan | nan | nan |
| 67 | NCI-2013-00046 | NCT01771107 | A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma | Inclusion | Participants must have previously untreated HIV-classical HL (cHL), with the exception of up to 14 consecutive days of steroids, emergency radiation, or 1 prior cycle of cyclophosphamide to reduce tumor burden and improve hyperbilirubinemia in the setting of lymphoma related liver involvement Participants must discontinue use of the following agents within 7 days prior to therapy * Strong CYP3A4 inhibitors that treat HIV * If patients are taking any of these excluded medications, they must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy HIV positive; documentation of HIV-1 infection by means of any one of the following: * Documentation of HIV diagnosis in the medical record by a licensed health care provider; * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider; * HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL; * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible * NOTE: A “licensed†assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies Patients already receiving erythropoietin or granulocyte colony stimulating factor (GCSF) for treatment of HIV-related cytopenia are eligible | HIV=YES AND Cytochrome P450 3A4 Inhibitor=NO AND (Erythropoietin=YES OR Erythropoietin=NO) AND (Granulocyte Colony-Stimulating Factor=YES OR Granulocyte Colony-Stimulating Factor=NO) | C15175=YES AND C111373=NO AND (C20429=YES OR C20429=NO) AND (C26078=YES OR C26078=NO) |
| 68 | NCI-2013-00370 | NCT01220583 | A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | Exclusion | Severe, active co-morbidity, defined as follows: * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol | (HIV=NO OR HIV =UNKNOWN) AND AIDS=NO) | (C15175=NO OR C15175 =C17998) AND C2851=NO) |
| 69 | NCI-2013-00426 | NCT01824836 | A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | nan | nan | nan | nan |
| 70 | NCI-2013-00500 | NCT01810913 | Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck | Exclusion | Severe, active co-morbidity, defined as follows: * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients | (HIV =NO) OR (HIV =UNKNOWN) (AIDS=NO) OR (Immunocompromised=NO) I believe this can be changed to AIDS=NO | C15175 =NO OR C15175 =C17998 AND (C2851=NO AND C14139=NO) |
| 71 | NCI-2013-00595 | NCT01817075 | Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT) | nan | nan | nan | nan |
| 72 | NCI-2013-00716 | NCT00978250 | Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU) | Exclusion | Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to: active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, ... that would limit compliance with study requirements | (HIV=NO OR HIV =UNKNOWN OR Immunocompromised=NO) AND (Healthy=YES)? | C15175=NO OR C15175 =C17998 OR (C14139=NO AND C115935=YES) |
| 73 | NCI-2013-00737 | NCT01822496 | A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC) | Exclusion | Severe, active co-morbidity, defined as follows: * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients | (HIV =NO) OR (HIV =UNKNOWN) OR (AIDS=NO) OR (Immunocompromised=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C2851=NO) OR (C14139=NO) |
| 74 | NCI-2013-00739 | NCT01822509 | A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation | Exclusion | Patients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded | (HIV =NO) OR (HIV =UNKNOWN) | (C15175 =NO) OR (C15175 =C17998) |
| 75 | NCI-2013-00740 | NCT01822522 | Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection | Inclusion/Exclusion | Inclusion: *Participants must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; any number of prior cancer therapies will be permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration; radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registration *Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic tests * Participating participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 8 weeks following study entry; as study-specific (antiretroviral-based) strata fill, however, only participants who are receiving the therapies eligible for the remaining open strata will be accrued Exclusion: Other clinically significant disorders such as: * Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; | HIV = Y | C15175 =YES |
| 76 | NCI-2013-00805 | NCT01244737 | A Phase II Study of [18F] FLT for PET Imaging of Brain Tumors in Children | nan | nan | nan | nan |
| 77 | NCI-2013-00826 | NCT01841723 | A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia | Exclusion | Human immunodeficiency virus (HIV)-positive patients will be eligible unless they have been previously diagnosed with an acquired immune deficiency syndrome (AIDS)-defining illness | HIV | (C15175 =NO) OR (C15175 =C17998) OR (C15175=YES AND C2851=NO) |
| 78 | NCI-2013-00858 | NCT01849146 | Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma | Exclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO) |
| 79 | NCI-2013-00875 | NCT01901094 | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy | nan | nan | nan | nan |
| 80 | NCI-2013-00877 | NCT01851369 | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas | Exclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO) |
| 81 | NCI-2013-00890 | NCT01935934 | A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer | Exclusion | Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO) |
| 82 | NCI-2013-00998 | NCT01881867 | A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Exclusion | Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible | (HIV =NO) OR (HIV =UNKNOWN) OR (Immunocompromised=NO) OR (HIV =YES AND HAART=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C14139=NO) OR (C15175 =YES AND C94631=NO) |
| 83 | NCI-2013-01132 | NCT01534598 | Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors | Exclusion | Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, known human immunodeficiency virus (HIV) infection requiring protease inhibitor therapy, ... that would limit compliance with study requirements | (HIV =NO) OR (HIV =UNKNOWN) OR (Immunocompromised=NO) OR (HIV =YES AND HIV Protease Inhibitor=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C14139=NO) OR (C15175 =YES AND C97366=NO) |
| 84 | NCI-2013-01272 | NCT01897012 | A Phase 1 Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas | nan | nan | nan | nan |
| 85 | NCI-2013-01275 | NCT01896999 | A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma | Inclusion | PHASE I: Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a cluster of differentiation 4 (CD4) count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded PHASE II: HIV positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND CD4>400 {cells}/mm3 AND HAART=YES) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C103810>400 {cells}/mm3 AND C94631=YES) |
| 86 | NCI-2013-01320 | NCT01902173 | Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer | Inclusion | Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3) | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO AND CD4>=500 {cells}/mm3)} | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO AND C103810>=500 {cells}/mm3)} |
| 87 | NCI-2013-01340 | NCT01953588 | ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study | nan | nan | nan | nan |
| 88 | NCI-2013-01357 | NCT01912625 | A Phase 1 Study of Trametinib in Combination with Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer | Exclusion | Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications HIV-positive patients on combination antiretroviral therapy are ineligible | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND HAART=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C94631=NO) |
| 89 | NCI-2013-01368 | NCT01925131 | A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia) | Inclusion | Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration: * CD4+ cells >= 350/mm^3 (nadir) * Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART * No zidovudine or stavudine as part of cART Patients who are HIV+ and do not meet all of these criteria are not eligible for this study | (HIV =NO) OR (HIV =UNKNOWN) OR (HIV =YES AND CD4>=350 {cells}/mm3 AND Viral Load<50 {copies}/mm3 AND HAART=YES) OR (HIV=YES AND CD4>=350 {cells}/mm3 AND Viral Load<25000 {copies}/mm3 AND HAART=NO) AND (Zidovudine=NO) AND (Stavudine=NO) | (C15175 =NO) OR (C15175 =C17998) OR (C15175 =YES AND C103810>=350 {cells}/mm3 AND C92544<50 {copies}/mm3 AND C94631=YES) OR (C15175=YES AND C103810>=350 {cells}/mm3 AND C92544<25000 {copies}/mm3 AND C94631=NO) AND (C947=NO) AND (C1428=NO) |
| 90 | NCI-2013-01452 | NCT00942877 | Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma | Exclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | (HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO) | (C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO) |
| 91 | NCI-2013-01474 | NCT01273155 | Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction | Exclusion | Human immunodeficiency virus (HIV) positive patients who are not on retroviral therapy will not be excluded from cohort 1, the normal liver function cohort * HIV positive patients who are not on retroviral therapy will be excluded from cohorts 2-4 HIV-positive patients on combination antiretroviral therapy are ineligible | (HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO AND (Abnormal Liver Function Test=NO OR Abnormal Liver Function Test=YES)) | (C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO AND (C122516=NO OR C122516=YES)) |
| 92 | NCI-2013-01475 | NCT01273168 | Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors | nan | nan | nan | nan |
| 93 | NCI-2013-01491 | NCT01362803 | A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | Exclusion | Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) will be excluded; patients with HIV who have adequate cluster of differentiation (CD)4 count, not requiring antiretroviral medication will not be excluded | (HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND CD4=Sufficient {cells}/mm3 AND HAART=NO) | (C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C103810=C63351 {cells}/mm3 AND C94631=NO) |
| 94 | NCI-2013-01496 | NCT01391962 | A Phase II Trial in Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression | Exclusion | Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible | (HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO) | (C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO) |
| 95 | NCI-2013-01520 | NCT01572493 | A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers | Exclusion | Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infection | HIV=NO OR HIV =UNKNOWN | C15175=NO OR C15175 =C17998 |
| 96 | NCI-2013-01568 | NCT01748825 | A Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors | Exclusion | Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible | (HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO) | (C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO) |
| 97 | NCI-2013-01588 | NCT01827384 | Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors | Exclusion | TUMOR BIOPSY SEQUENCING: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible | (HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND HAART=NO) | (C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C94631=NO) |
| 98 | NCI-2013-01602 | NCT01922076 | A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas | nan | nan | nan | nan |
| 99 | NCI-2013-01639 | NCT01964300 | Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma | nan | nan | nan | nan |
| 100 | NCI-2013-01702 | NCT02004275 | A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs.Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy | Inclusion | Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following: * No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness * Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 * Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 * Please note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4 | (HIV=NO) OR (HIV =UNKNOWN) OR (HIV=YES AND AIDS=NO AND AIDS-Related Disorder =NO AND CD4> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND HAART=NO) OR (HIV=YES AND AIDS=NO AND AIDS-Related Disorder =NO AND CD4> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND HAART=YES AND Viral Load< 50 {copies}/mm3) | (C15175=NO) OR (C15175 =C17998) OR (C15175=YES AND C2851=NO AND C4991=NO AND C103810> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND C94631=NO) OR (C15175=YES AND C2851=NO AND C4991=NO AND C103810> 350 {cells}/mm3 AND Treatment-sensitive HIV=YES AND C94631=YES AND C92544< 50 {copies}/mm3) |